Eli Lilly reported Phase III data for its weight loss drug retatrutide showing strong dose-dependent efficacy, with up to 30% weight loss at 104 weeks in patients with BMI over 35. UBS analysts highlight the drug's potential to differentiate itself in the obesity market, especially against generic competitors expected to deliver around 15% weight loss. Safety and tolerability are consistent with expectations, with manageable side effects such as nausea and diarrhea. Eli Lilly aims to position retatrutide primarily for patients with BMI above 35 and sees peak sales potential of $8-10 billion, with additional upside from early-stage metabolic disease programs.
The Vanguard Dividend Appreciation Index Fund ETF (VIG) has posted a modest 5% gain year-to-date, underperforming the broader market due to rising long-term Treasury yields, which compete with dividend yields. While dividend growth continues, investo...
Eli Lilly's Phase 1b Heart-2 trial showed that a single intravenous dose of VERVE-102 significantly lowered PCSK9 protein and LDL cholesterol (LDL-C) in patients at high risk for cardiovascular disease, with reductions lasting up to 18 months. The tr...
Eli Lilly's experimental obesity drug retatrutide achieved a 28% body weight loss over 80 weeks in a pivotal phase III trial, surpassing Novo Nordisk's leading treatments Wegovy and Ozempic. While retatrutide shows higher efficacy, it also has a high...
Eli Lilly reported positive Phase 3 trial results for retatrutide, a triple hormone drug targeting obesity. Patients on the highest 12 mg dose lost an average of 28.3% of their body weight, with significant improvements in cardiovascular risk markers...
Eli Lilly announced it will present important clinical trial data at the 2026 ASCO Annual Meeting, including Phase 3 results for Retevmo (selpercatinib) as adjuvant therapy in RET fusion-positive non-small cell lung cancer and Verzenio (abemaciclib) ...
